Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Overview
CoChat Summary
TL;DR
This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.
Key findings
- A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
- In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
- In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
- The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.
Methods
- Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
- Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
- Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.
Limitations
- The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
- The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
- The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
What the sources say
- Not checked — no full text of the sourcecites [223] Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med source
- Disputedcites [259] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports fewer non-fatal myocardial infarctions with both drug classes in low-risk patients and fewer non-fatal strokes with GLP-1 receptor agonists. That contradicts the claim that no drug class benefits cardiovascular events in this group. The Discussion > Clinical uncertainties section cautions that trials generally did not include the lowest-risk patients and does not judge whether the absolute effects are clinically notable. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with any laboratory test, HbA1c measurement has limitations (2,52).”
What the sources say
- Supportedcites [2] Draznin, 2022, 6. Glycemic targets: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The “A1C Limitations” section (p. 2) explicitly says the A1C test is subject to limitations and that its measurement varies, as with any laboratory test. (LLM, conf=0.95)
- Supportedcites [52] American Diabetes Association Professional Practice Committee, 2022, 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The Fasting and 2-Hour Plasma Glucose section explicitly refers to “these limitations with A1C,” including lower diagnostic sensitivity and imperfect correlation with average glucose in some individuals. The Race/Ethnicity/Hemoglobinopathies section also notes that hemoglobin variants can interfere with A1C measurement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these multifaceted domains (heterogeneity across individual characteristics, social determinants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when attempting to integrate diabetes care into daily life (49).”
What the sources say
- Supportedcites [49] Young-Hyman, 2016, Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care source
The Introduction says complex environmental, social, behavioral, and emotional factors challenge people with diabetes and their families as they integrate care into daily life. Life Course Considerations identifies social determinants and person-based characteristics as factors providers should consider, while the Conclusions describes challenges to providing that care. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
What the sources say
- Supportedcites [39] Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, Lancet Diabetes Endocrinol source
The Abstract describes type 2 diabetes as highly heterogeneous and identifies age at diagnosis, BMI, and insulin resistance as clustering variables. It reports that the resulting clusters differed in patient characteristics and risk of complications, supporting the claimed variation. (LLM, conf=0.92)
- Supportedcites [40] Pigeyre, 2022, Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial, Diabetologia source
The Introduction describes heterogeneity in diabetes presentation and progression. The Results identify subgroups differing in age at diagnosis, BMI and insulin-resistance-related characteristics; the Abstract reports differences in renal outcomes between subgroups. Together, these passages support the cited statement about variation among people with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective (22,25 -30).”
What the sources say
- Not checked — no full text of the sourcecites [22] Draznin, 2022, 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022, Diabetes Care source
- Partly supportedcites [25] Chrvala, 2016, Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control, Patient Educ Couns sourceExperimental — accuracy not yet measured
The Introduction says evidence from randomized and observational studies suggests DSME is cost-effective. The citing sentence presents cost-effectiveness as a consistently demonstrated finding, whereas this review does not establish it; Practical implications says DSME must be cost-effective, not that the review found it to be so. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Pillay, 2015, Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis, Ann Intern Med source
- Not checked — no full text of the sourcecites [27] Zhao, 2017, Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, J Adv Nurs source
- Partly supportedcites [28] Odgers-Jewell, 2017, Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression, Diabet Med sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says group-based education for people with type 2 diabetes may be more cost-effective than individual education because it requires less time and funding. That qualified comparison does not establish the broader, unqualified claim that DSMES is cost-effective. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [29] He, 2017, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis, Endocrine source
- Not checked — no full text of the sourcecites [30] Chatterjee, 2018, Diabetes structured self-management education programmes: a narrative review and current innovations, Lancet Diabetes Endocrinol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
127 more claims · 71 with their cited sources checked
Create a free account to see all 237 claims and every source verdict.
- It may state two separate claims as one. 88
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DiRECT dietary intervention was highly costeffective and deliverable in primary care. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thus cost-savings might be greater. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be particularly important in young-onset T2D where higher rates of obesity, more rapid deterioration in blood glucose levels and earlier development of diabetes complications have been observed [9,95].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increase insulin secretion regardless of glycemia, typically resulting in 2–3 kg weight gain [44].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [44]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 20×
“Notably, the benefits of GLP-1 RA and SGLT2i for cardiovascular and renal outcomes have been found to be independent of metformin use, and thus these agents should be considered in people with established or high risk of CVD, HF, or CKD, independent of metformin use (173–175).”
BackgroundInfluential
Research works printed but not linked: 2
- Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
- Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med
Cited by
Items 201–300 of 2,053
Ahmad, A., & Sabbour, H. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02192-4 · Cited by 25
Rethinking weight loss treatments as cardiovascular medicine in obesity, a comprehensive review
Tuccinardi, D., Watanabe, M., Masi, D., Monte, L., Meffe, L. B., Cavallari, I., Nusca, A., Maddaloni, E., Gnessi, L., Napoli, N., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae171 · Cited by 32
Ruiz‐Pozo, V. A., Guevara‐Ramírez, P., Paz‐Cruz, E., Tamayo‐Trujillo, R., Cadena-Ullauri, S., Frías-Toral, E., Simancas‐Racines, D., Roshkova, Y. V. A., Reytor-González, C., & Zambrano, A. K. (2024) · Food and Agricultural Immunology · doi:10.1080/09540105.2024.2398042 · Cited by 30
Cases, A., Broseta, J. J., Marqués, M., Guldris, S. C., Mauro, J. C. J., Arroyo, R. A., & Ortíz, A. (2024) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2024.11.011 · Cited by 43
Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists
Chen, J., Cooper, M., & Coughlan, M. T. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101641 · Cited by 35
Kong, F., Zhao, Y., Zhang, W., Wang, X., Wu, T., Zhou, Z., Xu, Y., Xia, L., & Sun, T. (2026) · Nature Communications · doi:10.1038/s41467-025-67701-9 · Cited by 29
“Although our synthesis shows increased gastrointestinal AEs and treatment discontinuation related to AEs, these challenges can generally be managed in practice through low-dose initiation, gradual up-titration, and regular monitoring 49 .”
SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes
Mukhopadhyay, P., Sanyal, D., Chatterjee, P., Pandit, K., & Ghosh, S. K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad113 · Cited by 31
Dihoum, A., Rena, G., Pearson, E. R., Lang, C. C., & Mordi, I. R. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2196010 · Cited by 33
“’ ADA/ EASD 2022 [12] ‘Overall, for treatment of hyperglycemia, metformin remains the agent of choice in most people with diabetes, based on its glucose-lowering efficacy, minimal risk of hypoglycemia, lack of weight increase, and affordability.”
BackgroundMittman, B. G., Le, P. N. B., Payne, J. Y., Ayers, G. T., & Rothberg, M. B. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2303413 · Cited by 26
“The recently published consensus report from the American Diabetes Association and European Association for the Study of Diabetes recommending GLP-1RA/SGLT2i use among patients with T2D and comorbid renal/cardiovascular disease highlights growing support for wider use of these medications 32 .”
BackgroundCardiovascular and non‐renal complications of chronic kidney disease: Managing risk
Rossing, P. R., Hansen, T. W., & Kümler, T. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15747 · Cited by 36
“Current guidelines, developed before the FLOW results were available, include SGLT2 inhibitors for kidney and heart protection and GLP-1 receptor agonists for cardiovascular benefit 4,21 and will in the future probably also include the kidney benefit seen in FLOW.”
Self-citationMarassi, M., & Fadini, G. P. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.11.005 · Cited by 27
Zhang, W., Wang, Y., Zhang, X., Zhang, Y., Yu, W., Tang, H., & Yuan, W. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03190-8 · Cited by 30
Billings, L. K., Andreozzi, F., Frederiksen, M., Gourdy, P., Gowda, A., Ji, L., Pletsch‐Borba, L., Suzuki, R., Unnikrishnan, A. G., & Vianna, A. G. D. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00052-x · Cited by 31
Colin, I. M., Szczepanski, L. W., Gérard, A.-C., & Elosegi, J. A. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.1.16 · Cited by 29
“All of these disorders, beyond the progressive beta cell failure, derive from insulin resistance (IR).1 Among the many T2DM- associated complications, damage to the central and peripheral nervous systems is prevalent in people with T2DM.”
BackgroundInfluentialThe Final Frontier in Diabetes Care: Implementing Research in Real-World Practice
Green, J. B., Crowley, M. J., Sathish, T., Maruthur, N. M., & Oldenburg, B. F. (2024) · Diabetes Care · doi:10.2337/dci24-0001 · Cited by 32
Self-citationMetformin-Associated Gastrointestinal Adverse Events Are Reduced by Probiotics: A Meta-Analysis
Szymczak-Pajor, I., Drzewoski, J., Wenclewska, S., & Śliwińska, A. (2024) · Pharmaceuticals · doi:10.3390/ph17070898 · Cited by 30
“…of patient-centered pharmacotherapy and allows treatment with glucagon like peptide 1 receptor agonists (GLP-1 RA) and sodium glucose cotransporter type 2 inhibitors (SGLT-2i) to be initiated despite the use of metformin in patients with risk or existing renal and/or cardiovascular disease [4].”
BackgroundKannenberg, S., Voggel, J., Thieme, N., Witt, O., Pethahn, K. L., Schütt, M., Sina, C., Freckmann, G., & Schröder, T. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241266821 · Cited by 28
Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
Pohlman, N., Patel, P. N., Essien, U. R., Tang, J., & Joseph, J. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf295 · Cited by 28
Zhang, P., Mao, C., Sun, A., Yang, Y., Hou, Y., Fu, Z., Tousi, B., Leverenz, J. B., Pieper, A. A., Luo, Y., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70639 · Cited by 33
“8 15 Additionally, GLP-1 receptor agonists and DPP-4 inhibitors may alleviate downregulation of GLP-1 in the AD brain, 16 and GLP-1 receptor knockout is related to impaired cognitive function in a mouse model.”
Bica, I.-C., Pietroșel, V.-A., Salmen, T., Diaconu, C.-T., Fierbinteanu-Braticevici, C. G., Stoica, R. A., Suceveanu, A., & Stoian, A. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087184 · Cited by 27
“The Consensus Report ADA-EASD 2022 recommends SGLT-2i or GLP-1 RA as first-line therapy, irrespective of the use of metformin, in addition to medical nutrition therapy (MNT) to reduce the cardio-renal risk in high-risk patients with T2DM [3].”
BackgroundMethodNakhal, M. M., Jayaprakash, P., Aburuz, S., Sadek, B. S., & Akour, A. A. (2023) · Pharmaceuticals · doi:10.3390/ph16050769 · Cited by 26
“Moreover, according to the European Society of Cardiology (ESC), the SGLT2 inhibitors are prescribed as an independent treatment of HF with a reduced ejection fraction, regardless of the diabetic status [12,13].”
BackgroundStörmann, S., Meyhöfer, S. M., Groener, J. B., Faust, J., Schilbach, K., Seufert, J., & Vergès, B. L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1348990 · Cited by 32
Klein, K. R., Clemmensen, K. K. B., Fong, E., Olsen, S., Abrahamsen, T., & Lingvay, I. (2024) · Diabetes Care · doi:10.2337/dc23-1791 · Cited by 22
Allen, A. M., Charlton, M., Cusi, K. J., Harrison, S. A., Kowdley, K. V., Noureddin, M., & Shubrook, J. H. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2325332 · Cited by 29
“Additionally, in 2022, the American Diabetes Association (ADA) and EASD emphasized the role of diabetes medications in the management of MASLD [29], while in January 2024, the ADA updated their guidance on the management of MASLD to include similar clinical practice recommendations to those from…”
BackgroundRuiz-León, A. M., Casas, R. M., Castro‐Barquero, S., Alfaro-González, S., Radeva, P. I., Sacanella, E., Casanovas-Garriga, F., Pérez-Gesalí, A., & Estruch, R. (2025) · Journal of Medical Internet Research · doi:10.2196/58319 · Cited by 45
“Consequently, numerous mobile health (mHealth) apps have been developed as innovative tools to enhance self-management of T2D and prevent macrovascular and microvascular complications [6-12].”
Kim, T. H., Lee, K., Park, S., Oh, J., Park, J., Jo, H., Lee, H., Cho, J., Wen, X., Cho, H., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16376 · Cited by 37
Pedersen, S. D., Giorgino, F., Umpierrez, G., Thieu, V. T., Rodríguez, A., Nicolay, C., Fernández Landó, L., Karanikas, C. A., & Kiljanski, J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15140 · Cited by 22
“Weight management has been recognized as a critical element of treatment of people with T2D, and it is considered to be as important as the management of elevated blood glucose levels.(17) Even a modest amount of weight loss can improve glycaemia and improve other metabolic abnormalities.”
BackgroundCohen, C. M., Schechter, M., Rozenberg, A., Yanuv, I., Sehtman-Shachar, D. R., Fishkin, A., Rosenzweig, D., Chodick, G., Karasik, A., & Mosenzon, O. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000218 · Cited by 27
“patients with a measurement) 78 (10), (9331) 79 (10), (9299) Diabetes medications Metformin, n (%) 9211 (94) 9290 (95) Insulin, n (%) All 1933 (20) 1796 (18) Basal insulin 1785 (18) 1694 (17) Fast-acting insulin 634 (7) 610 (6) Sulfonylureas, n (%) 1389 (14) 1413 (14) Glucagon-like peptide-1 receptor agonists, n (%) 3…”
InfluentialDiabetes foot complications and standardized mortality rate in type 2 diabetes
Stedman, M., Robinson, A., Dunn, G., Meza‐Torres, B., Gibson, M., Reeves, N. D., Jude, E. B., Feher, M. D., Rayman, G. A., Whyte, M., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15260 · Cited by 24
“27 An 8-year prospective study in patients with T2D and neuropathy has shown that sedentary time was the strongest predictor of DFU development, even after adjustment for HbA1c, neuropathy, pedal pulses, motor nerve amplitude and physical activity.”
BackgroundMoreno, Ó., Reyes‐García, R., Pardo, I. M., Doulatram‐Gamgaram, V. K., Cases, C. C., Guillen‐Morote, C., Mendoza, N. A., Pérez, C. T., Cárdenas‐Salas, J., Martínez‐Fuster, S., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15431 · Cited by 24
Gallo, G., & Volpe, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052484 · Cited by 24
“…of the cardiovascular protective role of SGLT2i and GLP1-RA, the European Association for the Study of Diabetes, the American Diabetes Association [92], and the American College of Cardiology [93] recommend considering these pharmacological classes as add-on therapies in patients with type 2…”
BackgroundAbdrabou Abouelmagd, A., Abdelrehim, A. M., Bashir, M. N., Abdelsalam, F., Marey, A., Tanas, Y., Abuklish, D. M., & Belal, M. M. (2025) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2025.2456441 · Cited by 25
“Originally, given that weight loss is being increasingly acknowledged as a vital part of the treatment for T2DM, 29 one of the included trials in the efficacy meta-analysis tested retatrutide in patients with T2DM.”
Heo, J. H., Han, K. A., Hong, J. H., Seo, H.-A., Hong, E., Yu, J. M., Jung, H. S., & Soo, B. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0314 · Cited by 26
“…sodium-glucose co-transporter 2 (SGLT2) inhibitors have emerged as the standard of care for patients with T2DM and established atherosclerotic cardiovascular disease (ASCVD), congestive heart failure (CHF), or chronic kidney disease (CKD), as recommended by international treatment guidelines [4,5].”
BackgroundWarmbrunn, M. V., Attaye, I., Aron‐Wisnewsky, J., Rampanelli, E., van der Vossen, E. W. J., Hao, Y., Koopen, A. M., Bergh, P., Stols‐Gonçalves, D., Mohamed, N., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2370616 · Cited by 24
Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management
Alhomoud, I. S., Talasaz, A. H., Chandrasekaran, P., Brown, R., Mehta, A., & Dixon, D. L. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4607 · Cited by 28
“11 Consequently, they are often referred to as second-generation obesity pharmaco - therapies.”
Mao, X., Zhang, X., Lai, R., Cheung, K. S., Yuen, M., Cheung, R. C., Seto, W., & Nguyen, M. H. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.1096 · Cited by 36
“In addition, we evaluate the association between GLP-1RA vs DPP-4i and 17 types of individual components of primary outcomes including compensated cirrhosis, liver decompensation, myocardial infarction, stroke, heart failure, end-stage renal disease, and esophageal, stomach, colorectal, pancreatic,…”
Rashid, A. M., Khan, M. S., Cherney, D. Z. I., Mehta, A. N., Rangaswami, J., Shafi, T., & Butler, J. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000752 · Cited by 25
Zhu, X., Shi, M.-Q., Jiang, Z.-M., Xiao-Li, Tian, J., & Su, F. (2025) · BMC Public Health · doi:10.1186/s12889-025-22702-7 · Cited by 36
“Leverage International Guidelines: Utilize the 2022 consensus report by the American Diabetes Association and the European Association for the Study of Diabetes, which provides comprehensive guidance on managing diabetes and preventing CVD in high-risk populations [30].”
Mantovani, A., Taverna, A., Cappelli, D., Beatrice, G., Csermely, A., Sani, E., Byrne, C. D., & Targher, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012481 · Cited by 23
Tang, S., Shao, H., Ali, M. K., & Zhang, P. (2023) · Annals of Internal Medicine · doi:10.7326/m22-3051 · Cited by 22
How can physical activity facilitate a sustainable future? Reducing obesity and chronic disease
Stensel, D. J. (2023) · Proceedings of The Nutrition Society · doi:10.1017/s0029665123002203 · Cited by 26
Hermanns, N., Ehrmann, D., Finke-Gröne, K., Krichbaum, M., Roos, T., Haak, T., Freckmann, G., & Kulzer, B. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100702 · Cited by 25
Zuo, Z., Pang, W., Sun, W., Lu, B., Zou, L., Zhang, D., & Wang, Y. (2023) · Foods · doi:10.3390/foods12163139 · Cited by 23
“This requires the daily management of blood glucose and lipid levels, body weight, cardiovascular risk factors, and complications [6].”
BackgroundKleibert, M., Zygmunciak, P., Łakomska, K., Mila, K., Zgliczyński, W., & Mrozikiewicz‐Rakowska, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713038 · Cited by 26
“Although, among high-risk patients, where cardiorenal risk reduction is the primary target, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RA) are preferred [8].”
BackgroundTsukamoto, S., Tanaka, S., Yamada, T., Uneda, K., Azushima, K., Kinguchi, S., Wakui, H., & Tamura, K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15312 · Cited by 29
Rodriguez‐Valadez, J. M., Tahsin, M., Masharani, U. B., Park, M., Hunink, M. G. M., Yeboah, J., Li, L., Weber, E. S., Berkalieva, A., Avezaat, L., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032463 · Cited by 22
Kim, H., Choi, C. U., Rhew, K., Park, J., Lim, Y., Kim, M. G., & Kim, K. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117490 · Cited by 25
Luo, S., Zheng, X., Bao, W., Nie, S., Ding, Y., Yue, T., Zhou, Y., Hu, Y., Li, H., Yang, Q., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01854-9 · Cited by 24
“3 In patients who already had a longer duration of T2D and more chronic exposure to hyperglycemia, reports suggest the effects of such “ late ” insulin treatment regarding cardiovascular outcomes.”
BackgroundChen, M., Pan, P., Zhang, H., Li, R., Ren, D., & Jiang, B. (2024) · Food & Function · doi:10.1039/d4fo02316a · Cited by 22
Polkowska, A., Głowińska‐Olszewska, B., Tobiaszewska, M., & Bossowski, A. T. (2014) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.18544/pedm-20.02.0002 · Cited by 21
Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
Hinnen, D. A., & Kruger, D. F. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s188705 · Cited by 25
Chrysavgis, L., Kazanas, S., Bafa, K., Rozani, S., Koloutsou, M. E., & Cholongitas, Ε. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073832 · Cited by 27
“To this end, GLP-1 agonists have already shown beneficial effects on cardiovascular events and are now recommended for the treatment of T2DM, especially when complicated by atherosclerotic CV disease [121–123].”
BackgroundMudaliar, S. R. (2023) · Journal of the Indian Institute of Science · doi:10.1007/s41745-023-00357-w · Cited by 37
Zhang, X., & Marx, C. M. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.3.276 · Cited by 24
Current scientific evidence for why periodontitis should be included in diabetes management
Borgnakke, W. S. (2024) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1257087 · Cited by 38
Liu, M. R., Gu, W., Chen, L., Li, Y., Kuang, H., Du, J., Alvarez, A., Lauand, F., Souhami, E., Zhang, J., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15724 · Cited by 22
Experimental and Clinical Endocrinology & Diabetes
Hu, T. F. S. H. Y. C. Z. C. J. C. W. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-00000017 · Cited by 20
Physical activity guidelines for adults with type 2 Diabetes: Systematic review
Tonga, E., Worboys, H. M., Evans, R. A., Singh, S., Davies, M. J., Ng, G. A., & Yates, T. E. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111982 · Cited by 30
Self-citationDeshmukh, H., Wilmot, E. G., Choudhary, P., Ssemmondo, E., Barnes, D., Walker, N., Walton, C., Ryder, R. E. J., & Sathyapalan, T. (2025) · Diabetes Care · doi:10.2337/dc24-1833 · Cited by 26
Saldívar-Cerón, H. I., Vargas-Camacho, J. A., León‐Cabrera, S., Briseño-Díaz, P., Castañeda-Ramírez, A. E., Muciño-Galicia, A. E., & Díaz-Domínguez, M. R. (2025) · Scientia Pharmaceutica · doi:10.3390/scipharm93020026 · Cited by 25
Diabetic cardiomyopathy: insights into pathophysiology, diagnosis and clinical management
Chen, D., Sindone, A. P., Huang, M., Peter, K., & Jenkins, A. J. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.06.013 · Cited by 27
Lean diabetes is one end of the spectrum of type 2 diabetes and not a separate entity
Mohan, V., Pramodkumar, T. A., Deepa, M., Pradeepa, R., Ranjit Unnikrishnan, I., Routray, P., Tharunika, S., Lakshmi, N., Killivalavan, D., Ganesan, S., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112387 · Cited by 22
Caring for Patients With Diabetes in Stroke Neurology
Kernan, W. N., Forman, R., & Inzucchi, S. E. (2022) · Stroke · doi:10.1161/strokeaha.122.038163 · Cited by 26
Chew, B., Yusof, B. N. M., Lai, P. S. M., & Khunti, K. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1649 · Cited by 20
Fan, B., Lim, C. K. P., Poon, E. W. M., Lau, E. S. H., Wu, H., Yang, A., Shi, M., Tam, C. H. T., Wong, S. Y. S., Lee, E. K. P., et al. (2023) · Diabetes Care · doi:10.2337/dc22-2301 · Cited by 27
The foot in diabetes – a reminder of an ever-present risk
Craus, S., Mula, A., & Coppini, D. (2023) · Clinical Medicine · doi:10.7861/clinmed2022-0489 · Cited by 26
A look at duodenal mucosal resurfacing: Rationale for targeting the duodenum in type 2 diabetes
Hoyt, J. A., Cozzi, E., D’Alessio, D. A., Thompson, C. C., & Aroda, V. R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15533 · Cited by 21
Self-citationBuckeridge, C., Tsamandouras, N., Carvajal‐Gonzalez, S., Brown, L. S., Hernandez‐Illas, M., & Saxena, A. R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15643 · Cited by 20
Associations between diabetes mellitus and sensorineural hearing loss from humans and animal studies
Williams, E. D., & Rubio, M. E. (2024) · Hearing Research · doi:10.1016/j.heares.2024.109072 · Cited by 25
The first report of leukocytoclastic vasculitis induced by once-weekly subcutaneous semaglutide
Pinheiro, M. M., de Souza, L. G., Nunes, G. P., Martin, I. F., de Oliveira, Y. U., Pinheiro, F. M. M., Costa, L. N., Caprio, M., Della‐Morte, D., & Infante, M. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2386047 · Cited by 24
“Indeed, current international guidelines strongly recommend the use of GLP-1RAs (such as semaglutide) particularly in patients with T2DM and comorbid overweight/obesity and/or atherosclerotic cardiovascular disease (ASCVD) 30,31 .”
Dinarvand, D., Panthakey, J., Heidari, A., Hassan, A. M., & Ahmed, M. H. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14090924 · Cited by 22
Glycemic Management and Individualized Diabetes Care in Dialysis-Dependent Kidney Failure
Klein, K. R., Lingvay, I., Tuttle, K. R., & Flythe, J. E. (2024) · Diabetes Care · doi:10.2337/dci24-0081 · Cited by 29
β-Cell Mitochondrial Dysfunction: Underlying Mechanisms and Potential Therapeutic Strategies
Darwish, R., Alcibahy, Y., Abu-Sharia, G., & Butler, A. E. (2025) · Cells · doi:10.3390/cells14231861 · Cited by 26
Recent advances in the treatment of patients with obesity and chronic kidney disease
Wahab, R. A., COHEN, R. V., & le Roux, C. W. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2203517 · Cited by 25
“In the recent guideline, SGLT2i is considered to have an intermediate action in promoting weight loss and is an option in treating patients with obesity and T2D [33].”
BackgroundA review of the evidence on cardiovascular outcomes from obesity treatment
Wahab, R. A., & le Roux, C. W. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100071 · Cited by 21
“With rising evidence that both drugs reduce cardiovascular and renal outcomes [3], currently, broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease have taken place [34].”
BackgroundClinical Trial: Probiotics in Metformin Intolerant Patients with Type 2 Diabetes (ProGasMet)
Nabrdalik, K., Drożdż, K., Kwiendacz, H., Skonieczna‐Żydecka, K., Łoniewski, I., Kaczmarczyk, M., Wijata, A. M., Nalepa, J., Holleman, F., Nieuwdorp, M., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115650 · Cited by 22
The quality of care in type 1 and type 2 diabetes – A 2023 update of the AMD Annals initiative
Russo, G. T., Cosmo, S. D., Bartolo, P. D., Lucisano, G., Manicardi, V., Nicolucci, A., Rocca, A., Rossi, M. C., Cianni, G. D., & Candido, R. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111743 · Cited by 23
Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity
Horváth, L., Mráz, M., Jude, E. B., & Haluzík, M. (2024) · Drugs · doi:10.1007/s40265-024-02029-0 · Cited by 22
“Current guidelines for the treatment of type 2 diabetes name weight management as one of the core tenets of therapy [94] and GLP-1 receptor agonists (RAs) as the first injectable therapy to be used before the initiation of insulin.”
BackgroundRecent progress in the pharmacotherapy for obesity
Lu, J., Liu, P., Cai, M., Lv, T., Zhang, M., Yin, K., Cheng, J., & Zhang, G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177850 · Cited by 17
Valensi, P. E. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02436-3 · Cited by 24
“…considered in some conditions, such as in people with a contraindication or intolerance to metformin, or in subjects who do not reach their HbA 1c target in 3 months, and importantly in those with athero-sclerostic cardiovascular disease independently of their effect on glycemic control [136, 137].”
BackgroundRusso, G. T., Nicolucci, A., Lucisano, G., Rossi, M. C., Ceriello, A., Prattichizzo, F., Manicardi, V., Rocca, A., Bartolo, P. D., Cosmo, S. D., et al. (2024) · Diabetes · doi:10.2337/db24-0166 · Cited by 22
Basiri, R., & Cheskin, L. J. (2024) · Nutrients · doi:10.3390/nu16234005 · Cited by 26
“It is important to note that changes in very high blood glucose levels are clinically significant, even in the absence of statistical significance, given the known adverse effects of levels exceeding 250 mg/dL on the body [36,44,45].”
Wu, H.-L., Chen, J., Cata, J. P., Hsieh, C.-H., Cherng, Y., & Tai, Y. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.08.003 · Cited by 22
Efficacy and Safety of Meal Replacement in Patients With Type 2 Diabetes
Ye, W., Xu, L., Ye, Y., Zeng, F., Lu, X., Li, Y., & Liu, L. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad273 · Cited by 17
Management of Type 2 Diabetes in Frail Older Adults
Bahat, G., Özkök, S., & Petrović, M. (2023) · Drugs & Aging · doi:10.1007/s40266-023-01049-x · Cited by 27
“They are contraindicated in individuals at risk for medullary thyroid cancer and diabetic retinopathy [8, 63].”
BackgroundInfluentialWashirasaksiri, C., Sayabovorn, N., Ariyakunaphan, P., Kositamongkol, C., Chaisathaphol, T., Sitasuwan, T., Tinmanee, R., Auesomwang, C., Nimitpunya, P., Woradetsittichai, D., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-41523-5 · Cited by 21
“The diabetes statuses of the participants were stratified into the following 4 groups according to American Diabetes Association guidelines 69 : • “nondiabetic”: HbA1c < 5.7% • “prediabetes”: HbA1c > 5.7% but ≤ 6.4% • “newly diagnosed diabetes”: HbA1c ≥ 6.5% or use of diabetes medications after the…”
MethodInfluentialFurusawa, S., Nomoto, H., Yokoyama, H., Suzuki, Y., Tsuzuki, A., Takahashi, K., Miya, A., Kameda, H., Cho, K. Y., Takeuchi, J., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15393 · Cited by 19
Kabubii, Z. N., Mbaria, J. M., Mathiu, P. M., Wanjohi, J. M., & Nyaboga, E. N. (2024) · Diabetology · doi:10.3390/diabetology5010002 · Cited by 24
“Diabetes mellitus is managed well by the effective control of blood glucose levels through diet modification, physical exercise, maintaining reasonable body weight, monitoring lipid profile levels, and using appropriate medication when necessary [7].”
Chen, Y., Chang, H., Lin, Y., Chien, K., Hsieh, Y., Chung, F., Lin, C., Lip, G. Y. H., & Chen, S. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3775 · Cited by 20
Prato, S. D., Giorgino, F., Szafranski, K., & Poon, Y. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15703 · Cited by 19
“14,15 16 – 19 The high direct healthcare costs of diabetes in Italy are largely related to the costs of treating complications.”
Self-citationde Moraes, F. C. A., Morbach, V., Sano, V. K. T., Fernandes, L. R., Kreuz, M., & Kelly, F. A. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07384-1 · Cited by 21
Ichikawa, T., Okada, H., Hironaka, J., Nakajima, H., Okamura, T., Majima, S., Senmaru, T., Ushigome, E., Nakanishi, N., Hamaguchi, M., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14271 · Cited by 22
“However, the effectiveness of LCD varied according to the duration of intervention in previous reports 4 , and several studies showed that long-term LCD for > 12 months was not effective in lowering HbA1c levels more ef fi ciently than the comparator diet 7 – 9 .”
BackgroundJeon, J. Y., & Kim, D. J. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0317 · Cited by 26
“MACE, major atherosclerotic cardiovascular disease; AKI, acute kidney injury; DKA, diabetic ketoacidosis; UTI, urinary tract infection. ly those with comorbidities such as CVD, heart failure, and CKD [67-69].”
BackgroundLong-acting glucagon-like peptide-1 receptor agonist—status December 2018
Holst, J. J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.01.09 · Cited by 21
Sunaga, T., Yokoyama, A., Nakamura, S., Miyamoto, N., Watanabe, S., Tsujiuchi, M., Nagumo, S., Nogi, A., Maezawa, H., Mizukami, T., et al. (2020) · Cardiology Research · doi:10.14740/cr1078 · Cited by 18
Feng, Q., Che, L., Li, C., Zhan, J., Li, B., Wang, L., Chen, S., Zhou, X., Song, D., & He, C. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202500320 · Cited by 16
Narrative Review: Continuous Glucose Monitoring (CGM) in Older Adults with Diabetes
Wilson, A., Morrison, D., Sainsbury, C. A. R., & Jones, G. C. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01720-z · Cited by 21
“Improved sleep is of particular interest, given the emphasis on adequate sleep as a factor which may improve health outcomes and insulin sensitivity in the 2022 consensus on Type 2 Diabetes from the American Diabetes Association and the European Association for the Study of Diabetes [44, 45].”
Hankosky, E. R., He, X., Malik, R., Brumm, J. F., Wang, F., Niemeyer, A., Zhang, X. M., & Garvey, W. T. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16401 · Cited by 24
“2,7,28 The results from this indirect treat-ment comparison showed a mean difference in percent bodyweight reduction between tirzepatide 15 mg and semaglutide 2.4 mg ranging from 4.4% to 5.3%, with up to 2.2 times greater odds of achieving ≥ 5% weight reduction.”
InfluentialAristizábal-Colorado, D., Corredor-Rengifo, D., Sierra-Castillo, S., López-Corredor, C., Trujillo, D. A. V., Weir-Restrepo, D., Izquierdo‐Condoy, J. S., Ortiz‐Prado, E., Rico-Fontalvo, J. E., Gomez‐Mesa, J., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1605746 · Cited by 37
Steven, S., Kuntić, M., Münzel, T. F., & Daiber, A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100082 · Cited by 26
Metadata
- Authors
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Brigham and Women's Hospital (US)
- National Heart, Lung, and Blood Institute (US)
- American Diabetes Association (US)
- Duke University (US)
- Johns Hopkins University (US)
- Joslin Diabetes Center (US)
- 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- KU Leuven (BE)
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Medical University of Sofia (BG)
- 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-28
- Volume
- 45
- Issue
- 11
- Pages
- 2753-2786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC10008140
- OpenAlex
- W4296802076
- Cited by
- 2,104
- References
- 348
- Citations by year
- 2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
- FWCI
- 282.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- European Association for the Study of Diabetes
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.